Safety and clinical performance of a drug eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries: Pooled 12‐month outcomes of BIOSOLVE‐II and BIOSOLVE‐III

OBJECTIVES: Based on outcomes of the BIOSOLVE‐II study, a novel second generation drug‐eluting absorbable metal scaffold gained CE‐mark in 2016. The BIOSOLVE‐III study aimed to confirm these outcomes and to obtain additional 12‐month angiographic data. BACKGROUND: Bioresorbable scaffolds are intende...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Catheter Cardiovasc Interv
Main Authors: Haude, Michael, Ince, Hüseyin, Kische, Stephan, Abizaid, Alexandre, Tölg, Ralph, Alves Lemos, Pedro, Van Mieghem, Nicolas M., Verheye, Stefan, von Birgelen, Clemens, Christiansen, Evald Høj, Barbato, Emanuele, Garcia‐Garcia, Hector M., Waksman, Ron
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2018
Assuntos:
Coronary Artery Disease (E‐only Articles)
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6586164/
https://ncbi.nlm.nih.gov/pubmed/30079472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccd.27680
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares